中医药调控肝纤维化相关信号通路的研究进展。

The American journal of Chinese medicine Pub Date : 2024-01-01 Epub Date: 2024-09-30 DOI:10.1142/S0192415X24500666
Shihao Zheng, Chengyuan Xue, Size Li, Wenying Qi, Xiaobin Zao, Xiaoke Li, Wei Wang, Qiyao Liu, Xu Cao, Peng Zhang, Yongan Ye
{"title":"中医药调控肝纤维化相关信号通路的研究进展。","authors":"Shihao Zheng, Chengyuan Xue, Size Li, Wenying Qi, Xiaobin Zao, Xiaoke Li, Wei Wang, Qiyao Liu, Xu Cao, Peng Zhang, Yongan Ye","doi":"10.1142/S0192415X24500666","DOIUrl":null,"url":null,"abstract":"<p><p>Liver fibrosis is a common complication of chronic liver disease, significantly affecting patients' quality of life and potentially leading to cirrhosis and hepatocellular carcinoma. Despite advancements in modern medicine, the treatment of liver fibrosis remains limited and challenging. Thus, identifying new therapeutic strategies is of great clinical importance. Signaling pathways related to liver fibrosis play a crucial regulatory role in immune response and inflammation. Aberrant activation of specific pathways, such as the NF-κB signaling pathway, results in the overexpression of genes associated with liver inflammation and fibrosis, thereby promoting the progression of liver fibrosis. Chinese medicine offers unique potential advantages as a therapeutic approach. Recent studies have increasingly demonstrated that certain Chinese medicines can effectively treat liver fibrosis by regulating relevant signaling pathways. The active ingredients in these medicines can inhibit hepatic inflammatory responses and fibrotic processes by interfering with these pathways, thus reducing the severity of liver fibrosis. This paper aims to investigate the mechanisms of Chinese medicine in treating liver fibrosis and its modulation of related signaling pathways. Additionally, it discusses the prospects of the clinical application of these treatments and provides valuable references for further research and clinical practice.</p>","PeriodicalId":94221,"journal":{"name":"The American journal of Chinese medicine","volume":" ","pages":"1693-1728"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research Progress of Chinese Medicine in the Regulation of Liver Fibrosis-Related Signaling Pathways.\",\"authors\":\"Shihao Zheng, Chengyuan Xue, Size Li, Wenying Qi, Xiaobin Zao, Xiaoke Li, Wei Wang, Qiyao Liu, Xu Cao, Peng Zhang, Yongan Ye\",\"doi\":\"10.1142/S0192415X24500666\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Liver fibrosis is a common complication of chronic liver disease, significantly affecting patients' quality of life and potentially leading to cirrhosis and hepatocellular carcinoma. Despite advancements in modern medicine, the treatment of liver fibrosis remains limited and challenging. Thus, identifying new therapeutic strategies is of great clinical importance. Signaling pathways related to liver fibrosis play a crucial regulatory role in immune response and inflammation. Aberrant activation of specific pathways, such as the NF-κB signaling pathway, results in the overexpression of genes associated with liver inflammation and fibrosis, thereby promoting the progression of liver fibrosis. Chinese medicine offers unique potential advantages as a therapeutic approach. Recent studies have increasingly demonstrated that certain Chinese medicines can effectively treat liver fibrosis by regulating relevant signaling pathways. The active ingredients in these medicines can inhibit hepatic inflammatory responses and fibrotic processes by interfering with these pathways, thus reducing the severity of liver fibrosis. This paper aims to investigate the mechanisms of Chinese medicine in treating liver fibrosis and its modulation of related signaling pathways. Additionally, it discusses the prospects of the clinical application of these treatments and provides valuable references for further research and clinical practice.</p>\",\"PeriodicalId\":94221,\"journal\":{\"name\":\"The American journal of Chinese medicine\",\"volume\":\" \",\"pages\":\"1693-1728\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The American journal of Chinese medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1142/S0192415X24500666\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of Chinese medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1142/S0192415X24500666","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

肝纤维化是慢性肝病的常见并发症,严重影响患者的生活质量,并可能导致肝硬化和肝细胞癌。尽管现代医学不断进步,但肝纤维化的治疗方法仍然有限,且具有挑战性。因此,确定新的治疗策略具有重要的临床意义。与肝纤维化相关的信号通路在免疫反应和炎症中发挥着重要的调节作用。特定通路的异常激活,如NF-[配方: 见正文]B信号通路,会导致与肝脏炎症和纤维化相关的基因过度表达,从而促进肝纤维化的进展。中医药作为一种治疗方法具有独特的潜在优势。最近的研究越来越多地表明,某些中药可通过调节相关信号通路有效治疗肝纤维化。这些中药的有效成分可以通过干扰这些通路来抑制肝脏炎症反应和纤维化过程,从而减轻肝纤维化的严重程度。本文旨在研究中药治疗肝纤维化的机制及其对相关信号通路的调节作用。此外,本文还探讨了这些疗法的临床应用前景,并为进一步的研究和临床实践提供了有价值的参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Research Progress of Chinese Medicine in the Regulation of Liver Fibrosis-Related Signaling Pathways.

Liver fibrosis is a common complication of chronic liver disease, significantly affecting patients' quality of life and potentially leading to cirrhosis and hepatocellular carcinoma. Despite advancements in modern medicine, the treatment of liver fibrosis remains limited and challenging. Thus, identifying new therapeutic strategies is of great clinical importance. Signaling pathways related to liver fibrosis play a crucial regulatory role in immune response and inflammation. Aberrant activation of specific pathways, such as the NF-κB signaling pathway, results in the overexpression of genes associated with liver inflammation and fibrosis, thereby promoting the progression of liver fibrosis. Chinese medicine offers unique potential advantages as a therapeutic approach. Recent studies have increasingly demonstrated that certain Chinese medicines can effectively treat liver fibrosis by regulating relevant signaling pathways. The active ingredients in these medicines can inhibit hepatic inflammatory responses and fibrotic processes by interfering with these pathways, thus reducing the severity of liver fibrosis. This paper aims to investigate the mechanisms of Chinese medicine in treating liver fibrosis and its modulation of related signaling pathways. Additionally, it discusses the prospects of the clinical application of these treatments and provides valuable references for further research and clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信